Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib and Ramucirumab in Advanced ALK-rearranged Lung Cancers
NCT06007937Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib, ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2023; status: active, not recruiting.
02
Drugs
lorlatinibramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06007937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007937.